Tag: email

New ETF offers direct exposure to a digital asset used by global financial institutions for cross-border payments

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

Press contact: 
Antara Nandy
Tel.: +91 9674515119  
Email: antara.nandy@capgemini.com

Learn key insights from the 2025 "State of the Air" report and how Camfil’s IAQ solutions address air quality challenges for healthier indoor spaces.

～Record Participation for SBC Medical. 22 doctors Present Insights in Their Respective Fields～

BROOKLYN, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Pioneer Acquisition I Corp (Nasdaq: PACHU) (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “PACHU” beginning June 18, 2025. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “PACH” and “PACHW”, respectively. The underwriter has been granted a 45-day option to purchase up to an additional 3,300,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on June 20, 2025, subject to customary closing conditions.

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ:PCRX) on behalf of long-term stockholders following a class action complaint that was filed against Pacira on June 16, 2025 with a Class Period from August 2, 2023 – August 8, 2024. Our investigation concerns whether the board of directors of Pacira have breached their fiduciary duties to the company.

PHILADELPHIA, June 17, 2025 (GLOBE NEWSWIRE) -- Brandywine Realty Trust (the “Company”) (NYSE: BDN) announced today that its operating partnership, Brandywine Operating Partnership, L.P. (the “Operating Partnership”), has priced an underwritten public offering of $150 million of its 8.875% guaranteed notes due 2029 (the “Notes”). Interest on the Notes will be payable semi-annually on April 12 and October 12 of each year, commencing on October 12, 2025.